## (19) World Intellectual Property Organization

International Bureau





(43) International Publication Date 25 August 2005 (25.08.2005)

**PCT** 

## (10) International Publication Number WO 2005/077082 A2

(51) International Patent Classification:

Not classified

(21) International Application Number:

PCT/US2005/004281

(22) International Filing Date: 11 February 2005 (11.02.2005)

(25) Filing Language:

. 5.

English

(26) Publication Language:

English

(30) Priority Data: 60/543,756

11 February 2004 (11.02.2004)

(71) Applicant (for all designated States except US): UNI-VERTSITY OF VIRGINIA PATENT FOUNDATION [US/US]; 1224 West Main Street, Ste 1-110, Charlottesville, VA 22903 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): GRAY, LLoyd, S.


[US/US]; 2955 Cove Trce, Charlottesville, VA 22911 (US). MACDONALD, Timothy, L. [US/US]; P.O. Box 262, Ivy, VA 22945 (US).

- (74) Agent: GROLZ, Edward, W.; Scully, Scott, Murphy & Presser, 400 Garden City Plaza, Ste 300, Garden City, NY
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

[Continued on next page]

(54) Title: INHIBITING CAV3 ISOFORMS AND THE \$25B SPLICE VARIENTS FOR THE DIAGNOSIS AND TREATMENT OF CANCER

Time (sec)



[miberradil] (µM)

(57) Abstract: The invention provides a pharmaceutical composition comprising an antibody that specifically binds to a Cav3 isoform or its 825 splice variants The present invention also relates to compositions and methods for inhibiting cancer cell proliferation, preventing, treating and/or controlling cancer and/or related disorders in a patient by administering to the patient a therapeutically effective amount of the T type calcium channel selective inhibitor. A preferred T type calcium channel selective inhibitor is mibefradil.

**BEST AVAILABLE COPY** 

GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

## Published:

 without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.